[Update on 2-28-21: Since this thread was posted a large WHO study suggested Remdesivir does not significantly reduce mortality or even shorten hospital stay which is basically all it had been credited with doing. The WHO also recommends against the use of Remdesivir.
https://www.covid-19forum.org/index.php?topic=449.0https://www.covid-19forum.org/index.php?topic=366.0Also it seems that monoclonal antibodies like Regeneron's do little as well:
https://www.covid-19forum.org/index.php?topic=642.0Now compare those very expensive treatments with $5 Ivermectin that has been used by competent, intelligent, truth seeking doctors to treat COVID-19 in the U.S. ever since April:
https://www.covid-19forum.org/index.php?topic=571.0With stunning results in mass treatment in Peru mid-2020
https://www.covidtreatmentoptions.com/#ivermectin - end update]
I'm no scientist but it seems Gilead keeps getting lipstick put on their Remdesivir pig. When a drug cocktail is used, the most promoted credit always seems to go to Remdesivir, even though the NIH's own study found Remdesivir did not result in a statistically significant reduction in mortality.
So should credit have gone to Regeneron's REGN-COV2 in this case? For over 100 years we've known that administering antibodies works.
Convalescent plasma therapy worked great for the COVID patient in at this link:
https://www.covid-19forum.org/index.php?topic=247.msg323#msg323Consider that they also gave Trump "zinc, vitamin D, an antacid called famotidine, melatonin and aspirin". Now we know that zinc is key in preventing replication of the virus inside the cells. We also know that patients that are deficient in vitamin D have far worse outcomes than those that are D sufficient.
So what really brought Trump around the bend? A drug that the NIH declared does not result in a statistically significant reduction in mortality?
From other reports Remdesivir may be credited with reducing the number of days Trump spent under the weather, which is reported as Rem's main advantage. But then convalescent plasma therapy is credited with that as well, so maybe the shorter stay is also thanks to REGN-COV2?
https://www.itv.com/news/2020-10-03/what-is-regenerons-regn-cov2-the-experimental-covid-drug-given-to-trumpAfter the disappointing NIH trial rather than going back to the drawing board, Gilead instead plans on adding baricitinib, in an effort to put lipstick on their Remdesivir pig, which by now should be at the
unsurprising cost of $2,374 for a supply of 30 tablets.
https://www.covid-19forum.org/index.php?topic=19.0
